| gap-pubmed-20260411- | What drives the specific increase in T cells within the substantia nigra in Park | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How do the 28 overlapping genes in depleted subpopulations mechanistically contr | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms cause TH-enriched non-neuronal cells to be depleted in Parkinson | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does CRH-BP contribute to the etiology or treatment of CRH dysregulation dis | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neuroendocrinology |
| gap-pubmed-20260411- | What are the specific mechanisms by which CRH-BP modulates CRH activity at centr | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroendocrinology |
| gap-pubmed-20260411- | What are the novel functional roles of CRH-BP beyond its established inhibitory | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neuroendocrinology |
| gap-pubmed-20260411- | What specific neuroinflammatory pathways mediate PEL24-199's therapeutic effects | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does PEL24-199's non-competitive BACE1 modulation mechanistically reduce bot | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does PGC-1α coordinate its diverse functions across mitochondrial biogenesis | open | 0.76 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What molecular mechanisms underlie CNS-specific PGC-1α isoform functions in diff | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the causal relationship between altered DC indoleamine 2,3-dioxygenase e | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does persistent SARS-CoV-2 in the colon mechanistically drive neurodegenerat | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms explain why pro-inflammatory cytokines and neurofilaments are el | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Can restoring primary cilia structure and function actually provide therapeutic | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do primary cilia defects specifically impair mitochondrial function in subst | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which primary cilia structural abn | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines tissue-specific vulnerability when PHB2-mediated mitophagy is di | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does PHB2 depletion paradoxically activate PARL protease while destabilizing | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can LRRK2 G2019S-targeted anti-inflammatory drugs be developed for PD treatm | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which LRRK2 G2019S in glial cells | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What determines the regional specificity of calcification and cortical malformat | open | 0.72 | 0.00 | 2026-04-11 | 0 | | neurodevelopment |
| gap-pubmed-20260411- | How do OCLN mutations mechanistically cause the specific pattern of brain calcif | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do structural differences between HMW and fibrillar tau determine their dist | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does HMW tau induce stronger glial activation than fibrillar tau without cau | open | 0.86 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What molecular mechanisms enable HMW tau to propagate more rapidly than fibrilla | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines the temporal relationship between GSH depletion, AGE formation, | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do AGEs activate glial cells to produce superoxide and nitric oxide in the n | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What specific molecular mechanisms drive AGE-mediated transformation of soluble | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do dual GIP/GLP-1 receptor mechanisms differ from GLP-1 alone in neuroprotec | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular pathways by which tirzepatide prevents neurodege | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can mechanistic insights into BBB development and maintenance be translated | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What specific mechanisms determine which BBB cell type failure leads to neuroinf | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What is the temporal relationship between glucose metabolism restoration and cog | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does DSS selectively target IRS1/GSK3β/Wnt3a-β-catenin pathway versus other | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What neurophysiological mechanisms explain why superimposed electrical stimulati | resolved | 0.64 | 0.00 | 2026-04-11 | 0 | | motor-neuroscience |
| gap-pubmed-20260411- | How do melatonin's multiple mechanisms integrate to provide neuroprotection in A | open | 0.73 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the long-term side effects of chronic melatonin use in AD patients? | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the optimal dosage and timing of melatonin administration for AD prevent | investigating | 0.87 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do other rare RELN variants confer similar protection against autosomal dominant | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do both resilient cases show limited entorhinal tau despite different protec | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does RELN-COLBOS signaling mechanistically confer resilience despite extreme | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can senotherapeutics be optimized to cross the blood-brain barrier and targe | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms determine subtype-specific senescent phenotypes in different bra | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does the p62-targeting small molecule specifically reactivate mitophagy? | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What causes mitophagy suppression during cellular senescence and aging? | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does mitochondrial superoxide specifically initiate basal mitophagy signalin | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What endosomal mechanisms mediate enhanced tau release from AD synapses upon dep | open | 0.74 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does synaptic tau abundance reconcile with the established dogma of tau as p | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms drive C-terminal truncation of tau specifically at syn | open | 0.80 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does the UBIAD1-apolipoprotein E interaction contribute to corneal lipid acc | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |